PD-L1/CD274 mychis fusion protein
种属
human
纯度
>90 %, SDS-PAGE
标签
Myc & 6*His
生物活性
未测试
验证数据展示
产品信息
| 纯度 | >90 %, SDS-PAGE |
| 内毒素 | <0.1 EU/μg protein, LAL method |
| 生物活性 | |
| 来源 | |
| 基因ID | 29126 |
| 蛋白编号 | |
| 预测分子量 | |
| SDS-PAGE | |
| 组分 | Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
| 复溶 | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
| 储存条件 |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
| 运输条件 | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
背景信息
Programmed cell death ligand 1 (PD-L1, also known as CD274 or B7-H1) is a 290 aa type I transmembrane protein that belongs to the B7 family of the Ig superfamily. PD-L1 is expressed by some hematopoietic cell types including macrophages, some activated T cells and B cells, DCs, and is further upregulated upon activation. It is also expressed on many nonhematopoietic cell types. PD-L1 is frequently upregulated in a wide variety of tumors, including melanoma, ovarian, lung, glioblastoma, breast, and pancreatic cancers. PD-L1 and PD-L2 are two ligands of PD-1. Engagement of PD-1 by PD-L1 or PD-L2 transduces a signal that inhibits T-cell proliferation, cytokine production, and cytolytic function. It is critical for the regulation of T-cell function during tolerance, autoimmunity and infection. Blockade of the PD-1/PD-L1 pathway has been developed for cancer immunotherapy.
参考文献:
1. Arlene H Sharpe, et al. (2007) Nat Immunol. 8(3):239-45. 2. Mary E Keir, et al. ( 2008) Annu Rev Immunol. 26:677-704. 3. James L Riley. (2009) Immunol Rev. 229(1):114-25. 4. Loise M Francisco, et al. ( 2010) Immunol Rev. 236:219-42. 5. Yanyan Han, et al. (2020) Am J Cancer Res. 10(3):727-742.